Literature DB >> 221546

Metabolic studies in an unusual case of asymptomatic familial hypobetalipoproteinemia with hypolphalipoproteinemia and fasting chylomicronemia.

D Steinberg, S M Grundy, H Y Mok, J D Turner, D B Weinstein, W V Brown, J J Albers.   

Abstract

A new kindred with asymptomatic hypobetalipoproteinemia is reported. The proband, age 67, differs from previously described cases in several respects: (a) unusually low levels of low density lipoprotein (LDL) cholesterol (4-8 mg/dl); (b) normal triglyceride levels; (c) low levels of high density lipoprotein; (d) mild fat malabsorption; and (e) a defect in chylomicron clearance. On a high-carbohydrate diet his plasma triglyceride levels, instead of rising, actually fell. Turnover of triglycerides in very low density lipoproteins (VLDL) was low (2.8 mg/kg per h). Fractional catabolic rate of LDL protein was just above the normal range (0.655/d) but net turnover was <10% of normal (0.65 mg/kg per d). The half-life of his chylomicrons was 29 min, five times the normal value. Postheparin lipoprotein lipase activity was normal and apolipoprotein C-II, the activator protein for lipoprotein lipase, was present and functional. Apolipoprotein C-III(1), however, was not detected in the VLDL fraction, a finding previously reported in patients with abetalipoproteinemia. Fecal excretion of cholesterol was almost twice normal; total sterol balance was increased by congruent with40%. The unusual features in the proband that distinguish him from previously described cases and from his affected first-degree relatives suggested that, in addition to the basic gene defect affecting LDL metabolism, he might have a second abnormality affecting clearance of chylomicrons and VLDL. The ratio of apolipoprotein E(3) to E(2) in his VLDL fraction was 0.93, just below the lower limit of normal, suggesting heterozygosity for E(3) deficiency. Whether or not this contributes to his hypertriglyceridemia remains to be established.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 221546      PMCID: PMC372117          DOI: 10.1172/JCI109451

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  On having no beta-lipoprotein. A syndrome comprising a-beta-lipoproteinaemia, acanthocytosis, and steatorrhoea.

Authors:  H B SALT; O H WOLFF; J K LLOYD; A S FOSBROOKE; A H CAMERON; D V HUBBLE
Journal:  Lancet       Date:  1960-08-13       Impact factor: 79.321

2.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

3.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

Review 4.  The low-density lipoprotein pathway and its relation to atherosclerosis.

Authors:  J L Goldstein; M S Brown
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Catabolism of very low density lipoprotein B apoprotein in man.

Authors:  M F Reardon; N H Fidge; P J Nestel
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

7.  Regulation of the activity of the low density lipoprotein receptor in human fibroblasts.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1975-11       Impact factor: 41.582

8.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

9.  Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects.

Authors:  L A Zech; S M Grundy; D Steinberg; M Berman
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

10.  Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia.

Authors:  S M Grundy; H Y Mok; L Zech; D Steinberg; M Berman
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

View more
  15 in total

Review 1.  Implications of the heart protection study for reducing coronary events in high-risk patients.

Authors:  William Virgil Brown; Warren Davis; Matthey Harris
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  The rationale for initiating treatment of hypercholesterolemia in young adulthood.

Authors:  Daniel Steinberg
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

3.  Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. Immunoenzymatic and biochemical characterization of seven cases of Anderson's disease.

Authors:  M E Bouma; I Beucler; L P Aggerbeck; R Infante; J Schmitz
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

4.  Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia.

Authors:  R P Dullaart; B Speelberg; H J Schuurman; R W Milne; L M Havekes; Y L Marcel; H J Geuze; M M Hulshof; D W Erkelens
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

5.  Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.

Authors:  S G Young; S T Hubl; R S Smith; S M Snyder; J F Terdiman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

6.  Hepatocyte nuclear factor 1 and C/EBP are essential for the activity of the human apolipoprotein B gene second-intron enhancer.

Authors:  A R Brooks; B Levy-Wilson
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

7.  Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100.

Authors:  S G Young; S J Bertics; L K Curtiss; B W Dubois; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

8.  Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice.

Authors:  G E Homanics; T J Smith; S H Zhang; D Lee; S G Young; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

9.  Reading-frame restoration with an apolipoprotein B gene frameshift mutation.

Authors:  M F Linton; V Pierotti; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia.

Authors:  S G Young; S J Bertics; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.